Roche Ends 2015 On Brighter Emerging Markets Note
This article was originally published in PharmAsia News
Executive Summary
Despite caution over emerging markets turmoil and a possible slowdown at the time of its third quarter results, in the end 2015 turned out well for Roche, with its pharma sales in key market China regaining momentum on the back of product expansions and oncology access schemes.
You may also be interested in...
Roche Exits Insulin Pumps Segment In India
Roche Diagnostics has exited the insulin pumps segment in India, but the Swiss multinational says it stays focused on the self-monitoring solutions segment for diabetics in a country that has more than 69 million people living with the chronic disease.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.